QRG Capital Management Inc. Has $2.87 Million Position in Hologic, Inc. $HOLX

QRG Capital Management Inc. lessened its stake in Hologic, Inc. (NASDAQ:HOLX) by 41.7% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 44,081 shares of the medical equipment provider’s stock after selling 31,513 shares during the quarter. QRG Capital Management Inc.’s holdings in Hologic were worth $2,872,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of HOLX. Greenleaf Trust grew its holdings in shares of Hologic by 5.1% during the 2nd quarter. Greenleaf Trust now owns 3,579 shares of the medical equipment provider’s stock valued at $233,000 after acquiring an additional 173 shares in the last quarter. Beverly Hills Private Wealth LLC grew its stake in Hologic by 3.6% in the first quarter. Beverly Hills Private Wealth LLC now owns 5,173 shares of the medical equipment provider’s stock valued at $320,000 after purchasing an additional 180 shares in the last quarter. Allworth Financial LP increased its position in Hologic by 46.0% in the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider’s stock worth $40,000 after purchasing an additional 216 shares during the last quarter. First American Bank raised its stake in shares of Hologic by 0.9% during the 2nd quarter. First American Bank now owns 28,705 shares of the medical equipment provider’s stock worth $1,870,000 after purchasing an additional 245 shares in the last quarter. Finally, Integrated Advisors Network LLC lifted its holdings in shares of Hologic by 5.4% during the 1st quarter. Integrated Advisors Network LLC now owns 5,603 shares of the medical equipment provider’s stock valued at $346,000 after buying an additional 289 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Analysts Set New Price Targets

HOLX has been the topic of a number of research reports. Royal Bank Of Canada upgraded Hologic from a “sector perform” rating to an “outperform” rating and increased their price objective for the stock from $72.00 to $87.00 in a report on Wednesday, August 6th. Citigroup raised shares of Hologic from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $60.00 to $80.00 in a research note on Wednesday, July 9th. Stephens reiterated an “overweight” rating and issued a $78.00 price objective on shares of Hologic in a report on Thursday, September 18th. Mizuho set a $75.00 target price on shares of Hologic in a research report on Thursday, July 31st. Finally, Morgan Stanley boosted their price target on Hologic from $65.00 to $69.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 31st. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $79.38.

Hologic Stock Performance

Shares of HOLX opened at $67.34 on Tuesday. The company has a market capitalization of $14.98 billion, a PE ratio of 27.94, a price-to-earnings-growth ratio of 2.34 and a beta of 0.63. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. Hologic, Inc. has a one year low of $51.90 and a one year high of $84.39. The company’s fifty day moving average price is $67.00 and its 200 day moving average price is $63.15.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.05 by $0.03. The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The business’s quarterly revenue was up 1.2% compared to the same quarter last year. During the same period in the prior year, the company earned $1.06 earnings per share. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insider Transactions at Hologic

In other Hologic news, CEO Stephen P. Macmillan sold 138,358 shares of Hologic stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total value of $9,265,835.26. Following the transaction, the chief executive officer directly owned 1,234,624 shares of the company’s stock, valued at $82,682,769.28. The trade was a 10.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 1.88% of the stock is owned by company insiders.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.